Can HRT prevent dementia? Separate the claim from the trials

Menopausal hormone therapy is not an established dementia-prevention treatment. The Menopause Society advises against estrogen-containing therapy for primary dementia prevention at the usual age of menopause. Randomized studies have not shown a consistent cognitive benefit, and a trial in older women found unfavorable cognitive outcomes for one regimen. FDA’s February 2026 removal of a probable-dementia statement from the boxed warnings of six products did not approve HRT to prevent dementia.¹²³⁴⁵

“Brain fog,” a cognitive test score and a dementia diagnosis are three different outcomes. A person can discuss bothersome symptoms during menopause without accepting a clinic’s claim that a hormone package protects the brain decades later. The evidence is easiest to understand when each study is matched to its population and endpoint.

Keep four questions on separate lines

This article addresses the primary-prevention claim, separate from immediate subjective symptoms. An advertisement can blur them by starting with “feel sharper” and ending with “protect against Alzheimer’s”; the second claim needs its own evidence.

What early-menopause trials tested

KEEPS-Cog randomized recently postmenopausal women to studied hormone regimens or placebo and assessed cognition and mood. It did not find a cognitive benefit from those regimens. That result does not mean no woman can feel better when vasomotor symptoms or sleep improve; it means the tested interventions did not produce a demonstrated cognitive-test benefit in that trial.²

ELITE-Cog explored a timing hypothesis by comparing estradiol started earlier versus later after menopause and assessing cognition. Its results did not support the idea that starting at the “right window” yields a proven cognitive advantage. A timing theory can be scientifically interesting without becoming an approved preventive service or a promise to patients.³

Neither study was a decades-long trial powered to prove dementia prevention. Their populations, formulations and tests differ from the Women’s Health Initiative Memory Study. It is inaccurate to combine them into one pooled “HRT prevents Alzheimer’s” figure, and equally inaccurate to use an older trial as a numerical risk estimate for every younger patient and every modern product.

Why the older-women trial still matters

WHIMS studied an estrogen-plus-progestin regimen in women aged 65 or older and reported an unfavorable global cognitive result. Its population and specific regimen matter. The trial does not prove that every hormone formulation at any age has the same cognitive effect, but it directly challenges a blanket claim that menopausal HRT is inherently neuroprotective.⁴

The Menopause Society’s statement reflects that evidence boundary: estrogen-containing HT is not recommended for primary prevention of dementia in women who experience menopause at the average age. The statement also recognizes legitimate uses for bothersome vasomotor symptoms and other defined conditions. Those legitimate uses do not require adding an unsupported prevention claim.¹

The 2026 FDA action was a label edit, not a new use

FDA announced in February 2026 that risk statements related to cardiovascular disease, breast cancer and probable dementia were removed from the boxed warning of six menopausal hormone therapy products. The announcement identifies the products and the wording change. It does not say FDA approved any of them for dementia prevention.⁵

The distinction matters because a boxed warning is a particular location in labeling. A sentence removed from that box is not the same as a clinical trial establishing benefit, a disappearance of all product warnings, or permission to market a prevention indication. The label-change guide examines that chronology; here the question is what prevention evidence actually shows.

If a clinic cites the FDA change as proof that HRT prevents dementia, ask for the exact FDA-approved indication and trial endpoint. “No longer in the box” and “prevents disease” are logically different claims.

A better way to discuss memory concerns

Describe the actual issue: forgetting appointments, difficulty concentrating, disrupted sleep, distress, or a change someone else has noticed. A clinician can consider the wider context, including medication effects, sleep, mood and other health issues, without promising that an HRT prescription is a dementia-prevention program.

If HRT is discussed for an established symptom, ask the prescriber to name that symptom and the product-specific indication. If the stated goal is prevention, ask what evidence demonstrates fewer future dementia diagnoses in a comparable population. A surrogate cognitive score and a boxed-warning headline do not fill that gap.

The hormone-therapy provider hub can help find a practice for a careful discussion. Bring the specific cognitive concern and any marketing claim you want explained. The useful outcome is a clear clinical question and an honest evidence boundary, not an untestable promise of brain protection.